Targeting polyelectrolyte networks in purulent body fluids to modulate bactericidal properties of some antibiotics

Infection and Drug Resistance

Volumn 11, Issue , 2018, Pages 77-86

  Bucki, Robert ^a   Durnaś, Bonita ^b   Wątek, Marzena ^b,c   Piktel, Ewelina ^a   Cruz, Katrina ^d   Wolak, Przemysław ^b   Savage, Paul B ^e   Janmey, Paul A ^d  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b JAN KOCHANOWSKI UNIVERSITY   (Poland)

^c Center Holy Cross Regional Hospital   (Poland)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Brigham Young University   (United States)

Author keywords

Antibiotic activity; Cathelicidin; Ceragenins; Cystic fibrosis; Depolymerizing factors; DNase 1; Polyelectrolyte network

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CERAGENIN CSA 13; COLISTIN; CRYSTAL VIOLET; DEOXYRIBONUCLEASE I; F ACTIN; GELSOLIN; POLYASPARTIC ACID; POLYELECTROLYTE; POLYMYXIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BIOFILM; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DNA STRUCTURE; FEMALE; HUMAN; LUMINESCENCE; MALE; MICROSCOPY; MIDDLE AGED; NONHUMAN; PROTEIN BLOOD LEVEL; PSEUDOMONAS AERUGINOSA; STRUCTURE ANALYSIS; SUPPURATION; VISCOELASTICITY; YOUNG ADULT;

EID: 85042082682     PISSN: None     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S145337     Document Type: Article

References (30)

1. Heijerman H. Infection and inflammation in cystic fibrosis: a short review. J Cyst Fibros. 2005;4(Suppl 2):3–5.
2. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010;23(2):299–323.
3. Moreau-Marquis S, Stanton BA, O’Toole GA. Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. Pulm Pharmacol Ther. 2008;21(4):595–599.
4. Walker TS, Tomlin KL, Worthen GS, et al. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun. 2005;73(6):3693–3701.
5. Pritt B, O’Brien L, Winn W. Mucoid Pseudomonas in cystic fibrosis. Am J Clin Pathol. 2007;128(1):32–34.
6. Sheils CA, Käs J, Travassos W, et al. Actin filaments mediate DNA fiber formation in chronic inflammatory airway disease. Am J Pathol. 1996;148(3):919–927.
7. Rubin BK. Mucus structure and properties in cystic fibrosis. Paediatr Respir Rev. 2007;8(1):4–7.
8. Tang JX, Wen Q, Bennett A, et al. Anionic poly(amino acid)s dissolve F-actin and DNA bundles, enhance DNase activity, and reduce the viscosity of cystic fibrosis sputum. Am J Physiol Lung Cell Mol Physiol. 2005;289(4):L599–L605.
9. Bals R, Weiner DJ, Meegalla RL, Accurso F, Wilson JM. Salt-independent abnormality of antimicrobial activity in cystic fibrosis airway surface fluid. Am J Respir Cell Mol Biol. 2001;25(1):21–25.
10. Broughton-Head VJ, Smith JR, Shur J, Shute JK. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics. Pulm Pharmacol Ther. 2007;20(6):708–717.
11. Bhatt JM. Treatment of pulmonary exacerbations in cystic fibrosis. Eur Respir Rev. 2013;22(129):205–216.
12. Davoodian K, Ritchings BW, Ramphal R, Bubb MR. Gelsolin activates DNase I in vitro and cystic fibrosis sputum. Biochemistry. 1997;36(32):9637–9641.
13. Ding B, Guan Q, Walsh JP, et al. Correlation of the antibacterial activities of cationic peptide antibiotics and cationic steroid antibiotics. J Med Chem. 2002;45(3):663–669.
14. Bucki R, Namiot DB, Namiot Z, Savage PB, Janmey PA. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. J Antimicrob Chemother. 2008;62(2):329–335.
15. Peeters E, Nelis HJ, Coenye T. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J Microbiol Methods. 2008;72(2):157–165.
16. Bucki R, Cruz K, Pogoda K, et al. Enhancement of Pulmozyme activity in purulent sputum by combination with poly-aspartic acid or gelsolin. J Cyst Fibros. 2015;14(5):587–593.
17. Voynow JA, Rubin BK. Mucins, mucus, and sputum. Chest. 2009; 135(2):505–512.
18. Rubin BK. Secretion properties, clearance, and therapy in airway disease. Transl Respir Med. 2014;2:6.
19. Weiner DJ, Bucki R, Janmey PA. The antimicrobial activity of the cathelicidin LL37 is inhibited by F-actin bundles and restored by gelsolin. Am J Respir Cell Mol Biol. 2003;28(6):738–745.
20. Perks B, Shute JK. DNA and actin bind and inhibit interleukin-8 function in cystic fibrosis sputa: in vitro effects of mucolytics. Am J Respir Crit Care Med. 2000;162(5):1767–1772.
21. Edmondson C, Davies JC. Current and future treatment options for cystic fibrosis lung disease: latest evidence and clinical implications. Ther Adv Chronic Dis. 2016;7(3):170–183.
22. Pressler T. Review of recombinant human deoxyribonuclease (rhD-Nase) in the management of patients with cystic fibrosis. Biologics. 2008;2(4):611–617.
23. Bucki R, Sostarecz AG, Byfield FJ, Savage PB, Janmey PA. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum. J Antimicrob Chemother. 2007;60(3):535–545.
24. Yu Q, Griffin EF, Moreau-Marquis S, Schwartzman JD, Stanton BA, O’Toole GA. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells. J Antimicrob Chemother. 2012;67(11): 2673–2681.
25. Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol. 2009;58(Pt 4):492–502.
26. Kaplan JB, LoVetri K, Cardona ST, et al. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo). 2012;65(2):73–77.
27. Guan YH, Lath DL, Graaf T, Lilley TH, Brook AH. Moderation of oral bacterial adhesion on saliva-coated hydroxyapatite by polyaspartate. J Appl Microbiol. 2003;94(3):456–461.
28. Robertson DM, Parks QM, Young RL, et al. Disruption of contact lens-associated Pseudomonas aeruginosa biofilms formed in the presence of neutrophils. Invest Ophthalmol Vis Sci. 2011;52(5):2844–2850.
29. Alipour M, Suntres ZE, Halwani M, Azghani AO, Omri A. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with cystic fibrosis. PLoS One. 2009;4(5):e5724.
30. Kruger P, Saffarzadeh M, Weber AN, et al. Neutrophils: Between host defence, immune modulation, and tissue injury. PLoS Pathog. 2015;11(3):e1004651.